
ESOCAP ANNOUNCES ISSUANCE OF PATENT IN SOUTH AFRICA FOR ITS SMART APPLICATION TECHNOLOGY IN THE UPPER GASTROINTESTINAL TRACT



Basel, Switzerland, March 28th, 2018

EsoCap AG announced today that the South Africa Patent and Trademark Office has issued the Patent No. 2017/03831 on March 28th, 2018 which is directed at the smart application technology enabling specific site-directed treatments of several diseases of the esophagus.

EsoCap AG is pursuing similar patent applications in other regions and countries including the USA, Europe, Japan as well as further strategic countries.

“The issuance of the South African patent confirms the novelty of the EsoCap technology” commented Isabelle Racamier, CEO of EsoCap AG. “We are committed to rapidly develop the EsoCap technology that may be beneficial in at least six therapeutic indications affecting 370 mio patients.”

Under a worldwide agreement, the University of Greifswald in Germany has granted EsoCap the exclusive rights for this unique drug delivery technology developed by the University of Greifswald. Up to now the local treatment of diseases of the esophagus was not possible due to the ultra-short transit time of conventional drug formulations. “The EsoCap smart application technology is definitely a paradigm shift for the effective and safe treatment of esophagus diseases” said Dr. Peter Stangier, Director Strategic Planning of EsoCap AG.

About EsoCap

EsoCap AG is a Swiss privately funded company based in Basel, Switzerland.

EsoCap’s vision is to improve the lives of patients with serious diseases through the development of a unique topical drug delivery platform for diseases of the upper gastrointestinal tract.

Topical treatment in the upper gastrointestinal tract is extremely difficult to achieve due to ultra-short transit times with less than two seconds from the mouth to the stomach.

EsoCap owns a unique drug delivery platform allowing the topical application of drug substances for the local treatment of diseases of the upper gastrointestinal tract.

For more information, please visit www.esocapbiotech.com.

Contact:

EsoCap AG
Malzgasse 9
4052 Basel
Switzerland

isabelle.racamier@esocapbiotech.com